Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial-Reference-Cited by-同舟云学术

Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial

Published:2023-09 Issue:3 Volume:87 Page:242-254
ISSN:0163-4453
Container-title:Journal of Infection
language:en
Short-container-title:Journal of Infection

Author:

Taucher Christian,Lazarus Rajeka,Dellago Hanna,Maurer Gabriele,Weisova Petronela,Corbic-Ramljak Irena^ORCID,Dubischar Katrin,Lilja Anders,Eder-Lingelbach Susanne,Hochreiter Romana,Jaramillo Juan Carlos,Junker Helga,Krammer Michael,Pusic Petra,Querton Benedicte^ORCID,Larcher-Senn Julian^ORCID,Hoffmann Markus^ORCID,Pöhlmann Stefan^ORCID,Finn Adam

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical)

Reference38 articles.

1. A global database of COVID-19 vaccinations;Mathieu;Nat Hum Behav,2021

2. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK;Voysey;Lancet,2021

3. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine;Polack;N Engl J Med [Internet],2020

4. Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil;Ranzani;Nat Commun 2022 131 [Internet],2022

5. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study;Watson;Lancet Infect Dis,2022

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. COVID-19 vaccine updates for people under different conditions;Science China Life Sciences;2024-07-29

2. Omicron breakthrough infections after triple‐dose inactivated COVID‐19 vaccination: A comprehensive analysis of antibody and T‐cell responses;Immunology;2024-03-10

3. RNAi-mediated inhibition of SARS-CoV-2: applications and challenges;Future Virology;2024-03-03

4. Autoimmune response after SARS-CoV-2 infection and SARS-CoV-2 vaccines;Autoimmunity Reviews;2024-03

5. Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up;Vaccines;2024-01-29